Anastrozole (Arimidex)
Prescription aromatase inhibitor for breast cancer that bodybuilders also use to lower estrogen; banned on the doping list.
The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Related comparisons
Anastrozol vs Letrozol vs ExemestaneDETAILED OVERVIEW
What is Anastrozole (Arimidex)?
Anastrozole (Arimidex) is a prescription aromatase inhibitor: it blocks the enzyme that turns male hormones into estrogen. In the United States it has been approved since 1995 for treating estrogen-sensitive breast cancer after menopause, and it is registered in Hungary and Poland as well. Bodybuilders and athletes also use it off-label, to keep estrogen low during steroid use and so avoid breast growth and water retention.
Pushing estrogen down too far, however, can cause joint and muscle pain, loss of sex drive, erection problems, low mood and sleep problems. It worsens cholesterol values, and with longer use it lowers bone density and raises the risk of fractures. It must not be used in pregnancy or breastfeeding, because it can cause fetal harm and miscarriage. On the anti-doping list, aromatase inhibitors are banned for male athletes both in and out of competition.
Mechanism
Reversible aromatase inhibitor; lowers estrogen levels by over 90%
Half-life
~50 hours (single daily dose, steady-state day 7)
Onset
E2 reduction measurable 24-48 h, full effect 5-7 days
Legal status
FDA + EMA Rx, HU + PL approved, WADA S4.1 banned
Anastrozol (Arimidex) does its intended job well as an aromatase inhibitor, but anecdotal reports consistently warn that it is easy to overdo and regret. Excess dosing can crash estrogen, leaving the user with low-E2 side effects (joint pain, mood collapse, libido loss, lipid issues) – outcomes that are decidedly worse than mildly elevated E2. It is not a compound to take blindly; dosing is guided by symptoms and ideally by bloodwork. Community accounts describe Arimidex as an excellent tool when E2 needs to be reliably and quickly lowered – used as-needed when high-E2 symptoms emerge and confirmed via labs. Arimidex is administered orally in small, controlled doses because of its high potency. Dosing is highly individual; too much can crash estrogen quickly. With a half-life around 2-3 days, twice-weekly administration is fairly common in community protocols.
⚠ Not clinical evidence – based on user accounts.
Data console
Lab data
Robertson JFR, Paridaens RJ, Lichfield J, Bradbury I, Campbell C . Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.. Eur J Cancer.
Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE . Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.. J Clin Oncol.
Miller WR, Anderson TJ, Evans DB . An integrated view of aromatase and its inhibition.. J Steroid Biochem Mol Biol.
Brueggemeier RW, Hackett JC, Diaz-Cruz ES. . Aromatase inhibitor mechanism: review. Endocr Rev. 2005;26(3):331-345..
Safety
Side effects, stop signs, contraindications
Side effects · 7
- Joint and muscle pain (arthralgia, myalgia), a common AI side effect, especially wrists, knees and hands, pronounced when E2 is over-suppressed
- Excessive estrogen suppression (crashed E2): loss of libido, erectile dysfunction, lethargy, depressed mood, sleep disturbance
- Adverse lipid profile: HDL decrease (~10-20%) and LDL rise, long-term cardiovascular risk, lipid monitoring required
- Reduced bone mineral density (osteopenia, osteoporosis) and fracture risk from chronic E2 deficit, DEXA monitoring advised with long-term use
- Hot flushes and sweating, a characteristic vasomotor symptom of estrogen suppression (common in clinical trials)
- Fatigue, headache and nausea; rarely mild, transient ALT/AST elevation (<2% incidence, serious hepatotoxicity extremely rare)
- Skin rash and rarely severe skin reactions (erythema multiforme, Stevens-Johnson syndrome described on the FDA label), allergic reactions
Contraindications · 7
- Pregnancy and breastfeeding are absolute contraindications (FDA Pregnancy Category X) – risk of fetal harm and pregnancy loss, contraception mandatory in women of childbearing potential
- Premenopausal women: anastrozole is ineffective and not indicated, as ovarian aromatase activity is not adequately suppressed, causing hormonal dysfunction
- Known hypersensitivity to anastrozole or any excipient (allergic reaction)
- Severe hepatic insufficiency (Child-Pugh C): CYP3A4/CYP1A2 metabolism is impaired, clinical data lacking, avoid
- Pre-existing osteoporosis or severe bone loss: chronic E2 suppression further worsens bone density and raises fracture risk
- Concurrent tamoxifen or estrogen-containing agents: tamoxifen lowers anastrozole plasma levels and estrogens negate the treatment, combination should be avoided
- Significantly adverse cardiovascular/lipid status (ischaemic heart disease, uncontrolled dyslipidemia): the AI can further worsen the lipid profile, close monitoring or avoidance warranted
Related Performance Compounds
Same therapeutic category
Studies
Related research and clinical findings
Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
Robertson JFR, Paridaens RJ, Lichfield J, Bradbury I, Campbell C
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J, Haynes B, Anker G, Dowsett M, Lønning PE
An integrated view of aromatase and its inhibition.
Miller WR, Anderson TJ, Evans DB
Aromatase inhibitor mechanism: review
Brueggemeier RW, Hackett JC, Diaz-Cruz ES.
Telegram
Have a question about Anastrozole (Arimidex)?
Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.


